Organigram Stock Story


USD 1.18  0.07  6.31%   

Powerbridge Technologies would continue recover faster as its shares surged to 23.88 percent against Organigram Hlds's 0.9346%. While some of us are excited about healthcare space, we will evaluate how stable are Organigram Hlds and Powerbridge Technologies fundamentals. We are going to examine some of the competitive aspects of both Organigram and Powerbridge.
Published over a month ago
View all stories for Organigram Hlds | View All Stories

Is Powerbridge more volatile than Organigram Hlds (NASDAQ:OGI)?

By analyzing existing technical and fundamental indicators between Organigram Hlds and Powerbridge, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Powerbridge with a short position in Organigram Hlds. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Organigram Hlds has an asset utilization ratio of 25.67 percent. This implies that the company is making $0.26 for each dollar of assets. An increasing asset utilization means that Organigram Hlds is more efficient with each dollar of assets it utilizes for everyday operations.

Watch out for price decline

Please consider monitoring Organigram Hlds on a daily basis if you are holding a position in it. Organigram Hlds is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Organigram Hlds stock to be traded above the $1 level to remain listed. If Organigram Hlds stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Organigram Hlds's Liquidity

Organigram Hlds financial leverage refers to using borrowed capital as a funding source to finance Organigram Hlds ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Organigram Hlds financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Organigram Hlds's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Organigram Hlds, but it might be worth checking our own buy vs. sell analysis

What is driving Organigram Hlds Investor Appetite?

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Organigram Hlds revenue. Based on the latest financial disclosure, Organigram Hlds reported 107.4 M of revenue. This is 98.59% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 98.86% higher than that of Organigram Hlds. As for Powerbridge Technologies we see revenue of 25.85 M, which is much higher than that of the Drug Manufacturers—Specialty & Generic

Organigram107.4 Million
Powerbridge25.85 Million
107.4 M
25.9 M

Organigram showing occurrence of lower volatility

Organigram Hlds current variance boosts over 21.49. Organigram Hlds exhibits very low volatility with skewness of 0.16 and kurtosis of -0.35. However, we advise investors to further study Organigram Hlds technical indicators to make sure all market info is available and is reliable. Organigram Hlds is a potential penny stock. Although Organigram Hlds may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Organigram Hlds. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Organigram instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Bottom Line On Organigram Hlds

While few other entities within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Organigram Hlds may offer a potential longer-term growth to stockholders. The inconsistency in the assessment between current Organigram valuation and our trade advice on Organigram Hlds is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Organigram Hlds.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Organigram Hlds. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to